Investigator

Daniel Baecker

PostDoc · Freie Universität Berlin, Pharmaceutical and Medicinal Chemistry

DBDaniel Baecker
Papers(2)
Loading of Dicarboxyl…Synthesis and biologi…
Collaborators(9)
Brigitte KircherHristo P. VarbanovHubert DescherIrena Pashkunova‐Mart…Francesco BaschieriRonald GustStefan SchwaigerAmelie ScherflerMartin Hermann
Institutions(4)
Freie Universitt Berl…Innsbruck Medical Uni…Universität InnsbruckMedical University of…

Papers

Loading of Dicarboxylatoplatinum(II)‐NHC Complexes in Bacterial Ghosts as an Advanced Development in Cancer Therapy

ABSTRACT This study aimed to improve the drug‐like properties of benzimidazole‐based Pt(II)‐N‐heterocyclic carbene (NHC) complexes, particularly by enhancing their water solubility and delivery to cancer cells. Accordingly, four new Pt(II) complexes of the benzimidazol‐2‐ylidene type, featuring monodentate carboxylato ligands, were prepared and their structures confirmed through a combination of spectroscopic and crystallographic techniques. Their stability in aqueous solution and cell culture medium was investigated by 1 H NMR spectroscopy and HPLC‐MS analysis. Cytotoxicity was assessed using the MTT assay in ovarian cancer cell lines (A2780wt (cisplatin sensitive) and A2780cis (cisplatin resistant)) and a noncancerous bone marrow stromal cell line (HS‐5). Most complexes exhibited cytotoxicity comparable to or exceeding that of carboplatin, with preferential activity toward cancer cells. Loading of all four Pt(II) complexes into bacterial ghost cells (BGs) derived from two different nonpathogenic bacterial strains, Escherichia coli (E. coli) Nissle 1917 and E. coli NM522 notably enhanced the intracellular accumulation and cytotoxicity. Furthermore, mechanistic studies demonstrated that all tested compounds, regardless of formulation, induced apoptosis. Their potential to trigger immunogenic cell death was also evaluated, though only a modest effect was observed on selected hallmarks. Collectively, these findings highlight the potential of dicarboxylatoplatinum(II)‐NHC complexes, particularly loaded into BG‐based formulations, as promising anticancer drug candidates.

66Works
2Papers
9Collaborators
Cell Line, TumorOvarian NeoplasmsKlebsiella InfectionsAcinetobacter InfectionsDrug Screening Assays, AntitumorApoptosisAlzheimer DiseaseLeukemia

Positions

2023–

PostDoc

Freie Universität Berlin · Pharmaceutical and Medicinal Chemistry

2025–

Guest lecturer

Pharos University in Alexandria · Pharmaceutical Chemistry

2020–

PostDoc

University of Greifswald · Pharmaceutical-Medicinal Chemistry

2022–

Guest lecturer

Hanoi University of Pharmacy · Pharmaceutical Chemistry

2020–

PostDoc

Innsbruck Medical University · Tyrolean Cancer Research Institute

2016–

PraeDoc, University Assistant

University of Innsbruck · Pharmaceutical Chemistry

Education

2015

University of Florida · Pharmaceutics

2014

University of Erlangen-Nuremberg · Institute of Pharmacy

Country

DE